Spyre Therapeutics Files 8-K on Shareholder Votes and Exhibits
Ticker: SYRE · Form: 8-K · Filed: Jun 2, 2025 · CIK: 1636282
| Field | Detail |
|---|---|
| Company | Spyre Therapeutics, Inc. (SYRE) |
| Form Type | 8-K |
| Filed Date | Jun 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing, financials
TL;DR
Spyre Therapeutics filed an 8-K for shareholder votes and financial exhibits.
AI Summary
On May 29, 2025, Spyre Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders and financial statements and exhibits. The company, formerly known as Aeglea BioTherapeutics, Inc. until March 11, 2015, is incorporated in Delaware and headquartered in Waltham, MA.
Why It Matters
This filing indicates important corporate actions and financial reporting by Spyre Therapeutics, providing transparency to investors regarding shareholder matters and financial health.
Risk Assessment
Risk Level: low — This is a routine filing reporting on corporate actions and financial statements, not indicating any immediate financial distress or significant operational changes.
Key Numbers
- 001-37722 — SEC File Number (Identifies the company's filing history with the SEC.)
- 46-4312787 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Spyre Therapeutics, Inc. (company) — Registrant
- Aeglea BioTherapeutics, Inc. (company) — Former company name
- May 29, 2025 (date) — Date of earliest event reported
- 20150311 (date) — Date of name change
- Delaware (jurisdiction) — State of incorporation
- Waltham, MA (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose is to report the submission of matters to a vote of security holders and to file financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on May 29, 2025.
What was Spyre Therapeutics, Inc. formerly known as?
Spyre Therapeutics, Inc. was formerly known as Aeglea BioTherapeutics, Inc.
In which state is Spyre Therapeutics, Inc. incorporated?
Spyre Therapeutics, Inc. is incorporated in Delaware.
Where are the principal executive offices of Spyre Therapeutics, Inc. located?
The principal executive offices are located at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 2, 2025 regarding Spyre Therapeutics, Inc. (SYRE).